Fact sheet 2007
Chairman and CEO | Daniel Vasella, M.D. |
Headquarters | Basel, Switzerland |
Major R&D sites | Basel, Switzerland |
Cambridge, Massachusetts | |
East Hanover, New Jersey | |
Horsham, England | |
Shanghai, China |
Major production sites | Basel, Schweizerhalle and Stein, Switzerland |
Grimsby, UK | |
Huningue, France | |
Kundl and Schaftenau, Austria | |
Kurtkoy, Turkey | |
Nyon, Switzerland | |
Ringaskiddy, Ireland | |
Singapore | |
Suffern, New York, US |
Web site address | www.novartis.com |
Stock exchange listings | Switzerland (virt-x) |
New York Stock Exchange | |
London Stock Exchange |
2007 sales | USD 38.1 billion |
Pharmaceuticals | USD 24.0 billion |
Vaccines and Diagnostics | USD 1.5 billion |
Sandoz | USD 7.2 billion |
Consumer Health | USD 5.4 billion |
2007 R&D spending | USD 6.4 billion |
Pharmaceuticals | USD 5.1 billion |
Vaccines and Diagnostics | USD 295 million |
Sandoz | USD 563 million |
Consumer Health | USD 301 million |
Corporate | USD 183 million |
Full-time associates (2007) | 98 200 |
Pharmaceuticals | 54 613 |
Vaccines and Diagnostics | 4 810 |
Sandoz | 23 087 |
Consumer Health | 13 956 |
Corporate | 1 734 |